Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.

Article Details

Citation

Mossner LD, Schmitz A, Theurillat R, Thormann W, Mevissen M

Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.

Am J Vet Res. 2011 Nov;72(11):1505-13. doi: 10.2460/ajvr.72.11.1505.

PubMed ID
22023129 [ View in PubMed
]
Abstract

OBJECTIVE: To identify and characterize cytochrome P450 enzymes (CYPs) responsible for the metabolism of racemic ketamine in 3 mammalian species in vitro by use of chemical inhibitors and antibodies. SAMPLE: Human, canine, and equine liver microsomes and human single CYP3A4 and CYP2C9 and their canine orthologs. PROCEDURES: Chemical inhibitors selective for human CYP enzymes and anti-CYP antibodies were incubated with racemic ketamine and liver microsomes or specific CYPs. Ketamine N-demethylation to norketamine was determined via enantioselective capillary electrophoresis. RESULTS: The general CYP inhibitor 1-aminobenzotriazole almost completely blocked ketamine metabolism in human and canine liver microsomes but not in equine microsomes. Chemical inhibition of norketamine formation was dependent on inhibitor concentration in most circumstances. For all 3 species, inhibitors of CYP3A4, CYP2A6, CYP2C19, CYP2B6, and CYP2C9 diminished N-demethylation of ketamine. Anti-CYP3A4, anti-CYP2C9, and anti-CYP2B6 antibodies also inhibited ketamine N-demethylation. Chemical inhibition was strongest with inhibitors of CYP2A6 and CYP2C19 in canine and equine microsomes and with the CYP3A4 inhibitor in human microsomes. No significant contribution of CYP2D6 to ketamine biotransformation was observed. Although the human CYP2C9 inhibitor blocked ketamine N-demethylation completely in the canine ortholog CYP2C21, a strong inhibition was also obtained by the chemical inhibitors of CYP2C19 and CYP2B6. Ketamine N-demethylation was stereoselective in single human CYP3A4 and canine CYP2C21 enzymes. CONCLUSIONS AND CLINICAL RELEVANCE: Human-specific inhibitors of CYP2A6, CYP2C19, CYP3A4, CYP2B6, and CYP2C9 diminished ketamine N-demethylation in dogs and horses. To address drug-drug interactions in these animal species, investigations with single CYPs are needed.

DrugBank Data that Cites this Article

Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
KetamineCytochrome P450 2C9ProteinHumans
Unknown
Substrate
Details
Drug Interactions
DrugsInteraction
Abrocitinib
Rucaparib
The metabolism of Abrocitinib can be decreased when combined with Rucaparib.
Abrocitinib
Pantoprazole
The metabolism of Abrocitinib can be decreased when combined with Pantoprazole.
Abrocitinib
Citalopram
The metabolism of Abrocitinib can be decreased when combined with Citalopram.
Abrocitinib
Ethambutol
The metabolism of Abrocitinib can be decreased when combined with Ethambutol.
Abrocitinib
Olanzapine
The metabolism of Abrocitinib can be decreased when combined with Olanzapine.
Abrocitinib
Omeprazole
The metabolism of Abrocitinib can be decreased when combined with Omeprazole.
Abrocitinib
Clozapine
The metabolism of Abrocitinib can be decreased when combined with Clozapine.
Abrocitinib
Voriconazole
The metabolism of Abrocitinib can be decreased when combined with Voriconazole.
Abrocitinib
Nilutamide
The metabolism of Abrocitinib can be decreased when combined with Nilutamide.
Abrocitinib
Esomeprazole
The metabolism of Abrocitinib can be decreased when combined with Esomeprazole.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more